- Phase II Study of Cyclophosphamide, Epirubicin, Vincristine, Prednisone, and Etoposide (CEOP-E) for Aggressive Non-Hodgkin 's Lymphoma
-
Kim JG, Sohn SK, Kim DH, Baek JH, Park TI, Lee KB
- KMID: 1778563
- J Korean Med Sci.
- 2004 Dec;19(6):820-825.
- doi: 10.3346/jkms.2004.19.6.820
The main objectives of the current study were to evaluate the efficacy and safety of a CEOP-E regimen for patients with aggressive non-Hodgkin's lymphoma (NHL). Fifty-one consecutive patients with newly... -
- CITED
-
- Close
- SHARE
-
- Close
- Locally advanced unresectable gastric cancer successfully resected after neoadjuvant chemotherapy with FADE regimen
-
Chung HC, Roh JK, Park YJ, Lee SI, Min JS, Lee JT, Lee KB, Kim BS
- KMID: 1121425
- Yonsei Med J.
- 1990 Mar;31(1):74-79.
- doi: 10.3349/ymj.1990.31.1.74
The prognosis of unresectable advanced gastric cancer is extremely poor. We tried a neoadjuvant chemotherapy in locally advanced unresectable stomach cancer diagnosed by initial explo-laparotomy. After chemotherapy with the FADE... -
- CITED
-
- Close
- SHARE
-
- Close
- ESHAP Salvage Therapy for Relapsed or Refractory Non-Hodgkin's Lymphoma
-
Choi CW, Paek CW, Seo JH, Kim BS, Shin SW, Kim YH, Kim JS
- KMID: 1127252
- J Korean Med Sci.
- 2002 Oct;17(5):621-624.
- doi: 10.3346/jkms.2002.17.5.621
The ESHAP regimen, a combination of the chemotherapeutic drugs etoposide, methylprednisolone (solumedrol), high-dose cytarabine (ara-C), and cisplatin, has been shown to be active against refractory or relapsed non-Hodgkin's lymphoma... -
- CITED
-
- Close
- SHARE
-
- Close
